Ann: Prescient Gains IP Rights in CAR-T Collaboration, page-30

With the resources/funds ptx have, I think it's important they play their best cards.

Ptx100 is a must, as it's targeting cancers where no drug exists. CAR-T is a super hot space too.

So it makes sense that with ptx200 they only go with the most advanced project.

Surely some big pharma will snap up ptx soon. We have seen billion dollar deals done recently for the first two projects I mentioned. Ptx200 just adds to the value, and reduces the risk to any buyer.

The ptx sp shot up last time following imu. I think imu is about to fly again soon, as their cf33 project starts trials. Again, I expect the ptx sp to follow them higher.

Cheers